<HTML>
<HEAD>
<TITLE>Page 45</TITLE>
<STYLE TYPE="text/css">
<!--
.pg{position:absolute;top:0px;left:0px;height:1056px;width:816px;}
BODY{font-size:13px;color:rgb(0,0,0);background-color:rgb(255,255,255);}
.ps0{position:absolute;top:1013px;left:690px;height:7px;width:21px;}
.ps1{position:absolute;top:111px;left:66px;height:13px;width:468px;}
.ps2{position:absolute;top:134px;left:66px;height:11px;width:511px;}
.ps3{position:absolute;top:153px;left:66px;height:11px;width:567px;}
.ps4{position:absolute;top:171px;left:66px;height:11px;width:537px;}
.ps5{position:absolute;top:189px;left:66px;height:11px;width:476px;}
.ps6{position:absolute;top:208px;left:66px;height:11px;width:520px;}
.ps7{position:absolute;top:226px;left:66px;height:11px;width:541px;}
.ps8{position:absolute;top:245px;left:66px;height:11px;width:534px;}
.ps9{position:absolute;top:263px;left:66px;height:11px;width:505px;}
.ps10{position:absolute;top:281px;left:66px;height:11px;width:543px;}
.ps11{position:absolute;top:300px;left:66px;height:11px;width:525px;}
.ps12{position:absolute;top:318px;left:66px;height:11px;width:495px;}
.ps13{position:absolute;top:336px;left:66px;height:11px;width:546px;}
.ps14{position:absolute;top:354px;left:66px;height:11px;width:568px;}
.ps15{position:absolute;top:373px;left:66px;height:11px;width:535px;}
.ps16{position:absolute;top:391px;left:66px;height:11px;width:480px;}
.ps17{position:absolute;top:409px;left:66px;height:11px;width:551px;}
.ps18{position:absolute;top:428px;left:66px;height:11px;width:544px;}
.ps19{position:absolute;top:446px;left:66px;height:11px;width:569px;}
.ps20{position:absolute;top:464px;left:66px;height:11px;width:557px;}
.ps21{position:absolute;top:483px;left:66px;height:11px;width:542px;}
.ps22{position:absolute;top:501px;left:66px;height:11px;width:552px;}
.ps23{position:absolute;top:520px;left:66px;height:11px;width:545px;}
.ps24{position:absolute;top:538px;left:66px;height:11px;width:537px;}
.ps25{position:absolute;top:556px;left:66px;height:11px;width:488px;}
.ps26{position:absolute;top:575px;left:66px;height:11px;width:98px;}
.ps27{position:absolute;top:601px;left:66px;height:11px;width:469px;}
.ps28{position:absolute;top:619px;left:66px;height:11px;width:550px;}
.ps29{position:absolute;top:637px;left:66px;height:11px;width:550px;}
.ps30{position:absolute;top:656px;left:66px;height:11px;width:553px;}
.ps31{position:absolute;top:674px;left:66px;height:11px;width:510px;}
.ps32{position:absolute;top:693px;left:66px;height:11px;width:521px;}
.ps33{position:absolute;top:711px;left:66px;height:11px;width:540px;}
.ps34{position:absolute;top:729px;left:66px;height:11px;width:566px;}
.ps35{position:absolute;top:748px;left:66px;height:11px;width:206px;}
.ps36{position:absolute;top:774px;left:66px;height:11px;width:543px;}
.ps37{position:absolute;top:792px;left:66px;height:11px;width:573px;}
.ps38{position:absolute;top:810px;left:66px;height:11px;width:563px;}
.ps39{position:absolute;top:829px;left:66px;height:11px;width:539px;}
.ps40{position:absolute;top:847px;left:66px;height:11px;width:572px;}
.ps41{position:absolute;top:865px;left:66px;height:11px;width:492px;}
.ps42{position:absolute;top:884px;left:66px;height:11px;width:574px;}
.ps43{position:absolute;top:902px;left:66px;height:11px;width:526px;}
.ps44{position:absolute;top:920px;left:66px;height:11px;width:563px;}
.ps45{position:absolute;top:939px;left:66px;height:11px;width:561px;}
.ps46{position:absolute;top:114px;left:410px;height:11px;width:569px;}
.ps47{position:absolute;top:132px;left:410px;height:11px;width:545px;}
.ps48{position:absolute;top:151px;left:410px;height:11px;width:557px;}
.ps49{position:absolute;top:169px;left:410px;height:11px;width:538px;}
.ps50{position:absolute;top:187px;left:410px;height:11px;width:545px;}
.ps51{position:absolute;top:206px;left:410px;height:11px;width:558px;}
.ps52{position:absolute;top:224px;left:410px;height:11px;width:157px;}
.ps53{position:absolute;top:250px;left:410px;height:11px;width:543px;}
.ps54{position:absolute;top:269px;left:410px;height:11px;width:536px;}
.ps55{position:absolute;top:287px;left:410px;height:11px;width:545px;}
.ps56{position:absolute;top:305px;left:410px;height:11px;width:499px;}
.ps57{position:absolute;top:324px;left:410px;height:11px;width:544px;}
.ps58{position:absolute;top:342px;left:410px;height:11px;width:514px;}
.ps59{position:absolute;top:368px;left:410px;height:11px;width:514px;}
.ps60{position:absolute;top:387px;left:410px;height:11px;width:510px;}
.ps61{position:absolute;top:405px;left:410px;height:11px;width:569px;}
.ps62{position:absolute;top:423px;left:410px;height:11px;width:525px;}
.ps63{position:absolute;top:442px;left:410px;height:11px;width:543px;}
.ps64{position:absolute;top:460px;left:410px;height:11px;width:546px;}
.ps65{position:absolute;top:478px;left:410px;height:11px;width:524px;}
.ps66{position:absolute;top:497px;left:410px;height:11px;width:570px;}
.ps67{position:absolute;top:515px;left:410px;height:11px;width:529px;}
.ps68{position:absolute;top:533px;left:410px;height:11px;width:510px;}
.ps69{position:absolute;top:552px;left:410px;height:11px;width:555px;}
.ps70{position:absolute;top:570px;left:410px;height:11px;width:513px;}
.ps71{position:absolute;top:588px;left:410px;height:11px;width:549px;}
.ps72{position:absolute;top:607px;left:410px;height:11px;width:466px;}
.ps73{position:absolute;top:625px;left:410px;height:11px;width:548px;}
.ps74{position:absolute;top:643px;left:410px;height:11px;width:427px;}
.ps75{position:absolute;top:662px;left:410px;height:11px;width:520px;}
.ps76{position:absolute;top:680px;left:410px;height:11px;width:510px;}
.ps77{position:absolute;top:698px;left:410px;height:11px;width:562px;}
.ps78{position:absolute;top:717px;left:410px;height:11px;width:530px;}
.ps79{position:absolute;top:735px;left:410px;height:11px;width:473px;}
.ps80{position:absolute;top:753px;left:410px;height:11px;width:539px;}
.ps81{position:absolute;top:772px;left:410px;height:11px;width:554px;}
.ps82{position:absolute;top:790px;left:410px;height:11px;width:523px;}
.ps83{position:absolute;top:808px;left:410px;height:11px;width:542px;}
.ps84{position:absolute;top:827px;left:410px;height:11px;width:566px;}
.ps85{position:absolute;top:845px;left:410px;height:11px;width:559px;}
.ps86{position:absolute;top:863px;left:410px;height:11px;width:475px;}
.ps87{position:absolute;top:882px;left:410px;height:11px;width:487px;}
.ps88{position:absolute;top:900px;left:410px;height:11px;width:547px;}
.ps89{position:absolute;top:918px;left:410px;height:11px;width:559px;}
.ps90{position:absolute;top:937px;left:410px;height:11px;width:338px;}
.ft0{font-size:8px;font-family:sans-serif;white-space:pre;}
.ft1{font-weight:bold;font-size:11px;font-family:sans-serif;white-space:pre;}
.ft2{font-family:sans-serif;white-space:pre;; border-color: black black black #FF0000; border-left-width: medium}
.ft3{font-weight:bold;font-size:14px;font-family:"Times New Roman",Times,serif;white-space:pre;}
.ft4{font-weight:bold;font-size:13px;font-family:"Times New Roman",Times,serif;white-space:pre;}
.ft5{font-size:12px;font-family:sans-serif;white-space:pre;}
.ft6{font-size:11px;font-family:sans-serif;white-space:pre;}
.em0{}
.em1{font-weight:bold;font-family:"Times New Roman",Times,serif;}
.em2{}
.em3{font-weight:normal;font-family:sans-serif;}
.em4{font-weight:normal;font-family:sans-serif;}
-->
</STYLE>
<script language="JavaScript">
<!--
function MM_reloadPage(init) {  //reloads the window if Nav4 resized
  if (init==true) with (navigator) {if ((appName=="Netscape")&&(parseInt(appVersion)==4)) {
    document.MM_pgW=innerWidth; document.MM_pgH=innerHeight; onresize=MM_reloadPage; }}
  else if (innerWidth!=document.MM_pgW || innerHeight!=document.MM_pgH) location.reload();
}
MM_reloadPage(true);
// -->
</script>
</HEAD>

<BODY>
<SPAN CLASS="ps0" style="left: 639px; top: 940px; height: 11px">
<p><SPAN CLASS="ft0">45</SPAN></p>
</SPAN> <SPAN CLASS="ps1" style="height: 13px; left: 25px; width: 320; top: 50px"><SPAN CLASS="ft1">H<SPAN CLASS="em0">YPERTENSION</SPAN><SPAN CLASS="em0"> 
</SPAN>&#160;<SPAN CLASS="em0">IN</SPAN>&#160;O<SPAN CLASS="em0">LDER</SPAN>&#160;P<SPAN CLASS="em0">ERSONS</SPAN></SPAN></SPAN> 
<SPAN CLASS="ps2" style="left: 25px; top: 69px; width: 325px"><SPAN CLASS="ft2">Hypertension 
is extremely common in older</SPAN></SPAN> <SPAN CLASS="ps3" style="left: 25px; top: 88px; width: 325px"><SPAN CLASS="ft2">Americans. 
&#160;Among Americans age 60 and older</SPAN></SPAN> <SPAN CLASS="ps4" style="left: 25px; top: 107px; width: 325"><SPAN CLASS="ft2">examined 
in the NHANES III, elevated blood</SPAN></SPAN> <SPAN CLASS="ps5" style="left: 25px; width: 325; top: 126px"><SPAN CLASS="ft2">pressure 
was found in 60 percent of non-</SPAN></SPAN> <SPAN CLASS="ps6" style="left: 25px; width: 325; top: 145px"><SPAN CLASS="ft2">Hispanic 
whites, 71 percent of non-Hispanic</SPAN></SPAN> <SPAN CLASS="ps7" style="left: 25px; width: 325; top: 164px"><SPAN CLASS="ft2">African 
Americans, and 61 percent of Mexican</SPAN></SPAN> <SPAN CLASS="ps8" style="left: 25px; width: 325; top: 181px"><SPAN CLASS="ft2">Americans.<SPAN CLASS="em2"><SUP>24<SPAN CLASS="em1">X</SPAN></SUP></SPAN>&#160;&#160;</SPAN><span class="ft3">Especially 
among older per-</span></SPAN> <SPAN CLASS="ps9" style="left: 25px; width: 325; top: 202px"><SPAN CLASS="ft3">sons, 
SBP is a better predictor of events</SPAN></SPAN> <SPAN CLASS="ps10" style="left: 25px; width: 325; top: 221px"><SPAN CLASS="ft3">(coronary 
heart disease, cardiovascular dis-</SPAN></SPAN> <SPAN CLASS="ps11" style="left: 25px; width: 325; top: 240px"><SPAN CLASS="ft3">ease, 
heart failure, stroke, end-stage renal</SPAN></SPAN> <SPAN CLASS="ps12" style="left: 25px; top: 259px; width: 325"><SPAN CLASS="ft3">disease, 
and all-cause mortality) than is</SPAN></SPAN> <SPAN CLASS="ps13" style="left: 25px; width: 325; top: 275px"><SPAN CLASS="ft4">DBP.<SPAN CLASS="em3"><SUP>26<SPAN CLASS="em1">Pr</SPAN></SUP></SPAN>&#160;&#160;<SPAN CLASS="em4">Recently, 
it has become clear that an</SPAN></SPAN></SPAN> <SPAN CLASS="ps14" style="left: 25px; width: 325; top: 296px"><SPAN CLASS="ft2">elevated 
pulse pressure (SBP minus DBP), which</SPAN></SPAN> <SPAN CLASS="ps15" style="left: 25px; width: 325; top: 315px"><SPAN CLASS="ft2">indicates 
reduced vascular compliance in large</SPAN></SPAN> <SPAN CLASS="ps16" style="left: 25px; width: 325; top: 334px"><SPAN CLASS="ft2">arteries, 
may be an even better marker of</SPAN></SPAN> <SPAN CLASS="ps17" style="left: 25px; width: 325; top: 353px"><SPAN CLASS="ft2">increased 
cardiovascular risk than either SBP or</SPAN></SPAN> <SPAN CLASS="ps18" style="left: 25px; width: 325; top: 371px"><SPAN CLASS="ft2">DBP 
alone.<SPAN CLASS="em2"><SUP>139<SPAN CLASS="em1">F</SPAN></SUP></SPAN>&#160;&#160;This 
is particularly relevant to</SPAN></SPAN> <SPAN CLASS="ps19" style="left: 25px; width: 325; top: 390px"><SPAN CLASS="ft2">older 
individuals who frequently have an isolated</SPAN></SPAN> <SPAN CLASS="ps20" style="left: 25px; width: 325; top: 410px"><SPAN CLASS="ft2">elevation 
of SBP (140 mm Hg or greater with a</SPAN></SPAN> <SPAN CLASS="ps21" style="left: 25px; width: 325; top: 429px"><SPAN CLASS="ft2">DBP 
below 90 mm Hg) (table 2). &#160;Those with</SPAN></SPAN> <SPAN CLASS="ps22" style="left: 25px; top: 448px; width: 325"><SPAN CLASS="ft2">stage 
1 isolated systolic hypertension are at sig-</SPAN></SPAN> <SPAN CLASS="ps23" style="left: 25px; width: 325; top: 467px"><SPAN CLASS="ft2">nificantly 
increased cardiovascular risk, but the</SPAN></SPAN> <SPAN CLASS="ps24" style="left: 25px; width: 325; top: 486px"><SPAN CLASS="ft2">benefits 
of treatment in those individuals have</SPAN></SPAN> <SPAN CLASS="ps25" style="left: 25px; width: 325; top: 505px"><SPAN CLASS="ft2">not 
yet been demonstrated in a controlled</SPAN></SPAN> <SPAN CLASS="ps26" style="left: 25px; top: 524px; width: 98px"><SPAN CLASS="ft5">trial.<SPAN CLASS="em2"><SUP>167<SPAN CLASS="em1">F</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps27" style="left: 25px; width: 325px; top: 552px"><SPAN CLASS="ft2">Primary 
hypertension is by far the most </SPAN></SPAN> <SPAN CLASS="ps28" style="left: 25px; top: 570px; width: 325px"><SPAN CLASS="ft2">common 
form of hypertension in older persons.</SPAN></SPAN> <SPAN CLASS="ps29" style="left: 25px; top: 589px; width: 325px"><SPAN CLASS="ft2">However, 
clinicians must recognize that certain</SPAN></SPAN> <SPAN CLASS="ps30" style="left: 25px; top: 608px; width: 325px"><SPAN CLASS="ft2">identifiable 
causes of hypertension (e.g., athero-</SPAN></SPAN> <SPAN CLASS="ps31" style="left: 25px; top: 627px; width: 325px"><SPAN CLASS="ft2">sclerotic 
renovascular hypertension, primary</SPAN></SPAN> <SPAN CLASS="ps32" style="left: 25px; top: 646; width: 325px"><SPAN CLASS="ft2">aldosteronism) 
may occur more frequently in</SPAN></SPAN> <SPAN CLASS="ps33" style="left: 25px; top: 665px; width: 325px"><SPAN CLASS="ft2">older 
persons, especially in those whose hyper-</SPAN></SPAN> <SPAN CLASS="ps34" style="left: 25px; top: 684px; width: 325px"><SPAN CLASS="ft2">tension 
first presented after age 60 or is resistant</SPAN></SPAN> <SPAN CLASS="ps35" style="left: 25px; top: 700px"><SPAN CLASS="ft2">to 
treatment.<SPAN CLASS="em2"><SUP>145<SPAN CLASS="em1">Pr</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps36" style="left: 25px; top: 726px; width: 325px"><SPAN CLASS="ft2">Blood 
pressure must be measured in older per-</SPAN></SPAN> <SPAN CLASS="ps37" style="left: 25px; top: 745; width: 325"><SPAN CLASS="ft2">sons 
with special care because some older persons</SPAN></SPAN> <SPAN CLASS="ps38" style="left: 25px; width: 325px; height: 11px; top: 764px"><SPAN CLASS="ft2">have 
pseudohypertension (falsely high sphygmo-</SPAN></SPAN> <SPAN CLASS="ps39" style="left: 25px; top: 783px; width: 325px"><SPAN CLASS="ft2">manometer 
readings) due to excessive vascular</SPAN></SPAN> <SPAN CLASS="ps40" style="left: 25px; top: 799px; width: 325px"><SPAN CLASS="ft2">stiffness.<SPAN CLASS="em2"><SUP>168</SUP></SPAN>&#160;&#160;In 
addition, more older persons with</SPAN></SPAN> <SPAN CLASS="ps41" style="left: 25px; top: 820; width: 325"><SPAN CLASS="ft2">hypertension, 
especially women, may have</SPAN></SPAN> <SPAN CLASS="ps42" style="left: 25px; width: 325px; height: 11px; top: 839"><SPAN CLASS="ft2">&#147;white-coat 
hypertension&#148; and excessive variabili-</SPAN></SPAN> <SPAN CLASS="ps43" style="left: 25px; top: 856; width: 325px"><SPAN CLASS="ft2">ty 
in SBP.<SPAN CLASS="em2"><SUP>169<SPAN CLASS="em1">X</SPAN></SUP></SPAN>&#160;&#160;In 
the absence of target organ</SPAN></SPAN> <SPAN CLASS="ps44" style="left: 25px; top: 877px; width: 325px"><SPAN CLASS="ft2">damage, 
clinicians should consider pseudohyper-</SPAN></SPAN> <SPAN CLASS="ps45" style="left: 25px; top: 896px; width: 325px"><SPAN CLASS="ft2">tension 
or &#147;white-coat hypertension&#148; and should</SPAN></SPAN> <SPAN CLASS="ps46" style="left: 369px; width: 300px; top: 50px"><SPAN CLASS="ft2">obtain 
readings outside the office (see chapter 2).</SPAN></SPAN> <SPAN CLASS="ps47" style="width: 300; left: 369px; top: 69px"><SPAN CLASS="ft2">In 
addition, older patients are more likely than</SPAN></SPAN> <SPAN CLASS="ps48" style="width: 300; left: 369px; top: 88px"><SPAN CLASS="ft2">younger 
patients to exhibit an orthostatic fall in</SPAN></SPAN> <SPAN CLASS="ps49" style="width: 300; left: 369; top: 107px"><SPAN CLASS="ft2">blood 
pressure and hypotension; thus, in older</SPAN></SPAN> <SPAN CLASS="ps50" style="width: 300; left: 369px; top: 126px"><SPAN CLASS="ft2">patients, 
blood pressure should always be mea-</SPAN></SPAN> <SPAN CLASS="ps51" style="width: 300; left: 369px; top: 145px"><SPAN CLASS="ft2">sured 
in the standing as well as seated or supine</SPAN></SPAN> <SPAN CLASS="ps52" style="width: 157px; left: 369; top: 161px"><SPAN CLASS="ft2">positions.<SPAN CLASS="em2"><SUP>170<SPAN CLASS="em1">X</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps53" style="left: 369; top: 189px; width: 300"><SPAN CLASS="ft2">Treatment 
of hypertension in older persons has</SPAN></SPAN> <SPAN CLASS="ps54" style="width: 300; left: 369px; top: 207px"><SPAN CLASS="ft2">demonstrated 
major benefits (figure 7). &#160;Large</SPAN></SPAN> <SPAN CLASS="ps55" style="width: 300; left: 369; top: 226px"><SPAN CLASS="ft2">trials 
of patients older than age 60 have shown</SPAN></SPAN> <SPAN CLASS="ps56" style="width: 300; left: 369; top: 245px"><SPAN CLASS="ft2">that 
antihypertensive drug therapy reduces</SPAN></SPAN> <SPAN CLASS="ps57" style="width: 300; left: 369px; top: 264px"><SPAN CLASS="ft2">stroke, 
CHD, cardiovascular disease, heart fail-</SPAN></SPAN> <SPAN CLASS="ps58" style="width: 300; left: 369px; top: 283px"><span class="ft2"><font color="#000000">ure, 
and mortality</font></span><font color="#000000"><SPAN CLASS="ft6">.<SPAN CLASS="em2"><SUP>140<SPAN CLASS="em1">Ra,</SPAN>171<SPAN CLASS="em1">Ra,</SPAN>172<SPAN CLASS="em1">Ra,</SPAN>173<SPAN CLASS="em1">Ra</SPAN>,17</SUP></SPAN></SPAN></font><SPAN CLASS="ft6"><SPAN CLASS="em2"><SUP>4<SPAN CLASS="em1">Ra</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps59" style="width: 300; left: 369; top: 308px; height: 19"><SPAN CLASS="ft2">Hypertension 
therapy in older persons, as in</SPAN></SPAN> <SPAN CLASS="ps60" style="width: 300; left: 369; top: 326px; height: 18"><SPAN CLASS="ft2">younger 
persons, should begin with lifestyle</SPAN></SPAN> <SPAN CLASS="ps61" style="width: 300; left: 369; top: 343px; height: 18"><SPAN CLASS="ft2">modifications.<SPAN CLASS="em2"><SUP>26<SPAN CLASS="em1">Pr</SPAN></SUP></SPAN><font color="#FFFFFF">&#160;&#160;</font>Older 
patients will respond to</SPAN></SPAN> <SPAN CLASS="ps62" style="width: 300; left: 367px; top: 362px; height: 22"><SPAN CLASS="ft2">modest 
salt reduction and weight loss.<SPAN CLASS="em2"><SUP>80<SPAN CLASS="em1">Ra</SPAN></SUP></SPAN><font color="#FFFFFF">&#160;</font>&#160;If</SPAN></SPAN> 
<SPAN CLASS="ps63" style="width: 300; left: 369; top: 383px; height: 19"><SPAN CLASS="ft2">goal 
blood pressure is not achieved, then phar-</SPAN></SPAN> <SPAN CLASS="ps64" style="width: 300; left: 369; top: 402px; height: 19"><SPAN CLASS="ft2">macologic 
treatment is indicated. &#160;The starting</SPAN></SPAN> <SPAN CLASS="ps65" style="width: 301px; left: 368px; top: 421px; height: 19px"><SPAN CLASS="ft2">dose 
in older patients should be about half of</SPAN></SPAN> <SPAN CLASS="ps66" style="width: 300; left: 369; top: 440px; height: 19"><SPAN CLASS="ft2">that 
used in younger patients.<font color="#FFFFFF"> &#160;<font color="#FF0000">Thiazide 
diuretics</font></font></SPAN></SPAN> <SPAN CLASS="ps67" style="width: 300; left: 369px; top: 459px; height: 19"><SPAN CLASS="ft2"><font color="#FF0000">or 
beta-blockers in combination with thiazide</font></SPAN></SPAN> <SPAN CLASS="ps68" style="width: 300; left: 369; top: 478px; height: 19"><SPAN CLASS="ft2"><font color="#FF0000">diuretics 
are recommended because they are</font></SPAN></SPAN> <SPAN CLASS="ps69" style="width: 300; left: 369; top: 497px; height: 19"><SPAN CLASS="ft2"><font color="#FF0000">effective 
in reducing mortality and morbidity in</font></SPAN></SPAN> <SPAN CLASS="ps70" style="width: 300; left: 369; top: 516px; height: 19"><SPAN CLASS="ft2"><font color="#FF0000">older 
persons with hypertension as shown in</font></SPAN></SPAN> <SPAN CLASS="ps71" style="width: 300; left: 369; top: 533px; height: 22"><SPAN CLASS="ft2"><font color="#FF0000">multiple 
randomized controlled trials.<SPAN CLASS="em2"><SUP>120<SPAN CLASS="em1">M,</SPAN>171<SPAN CLASS="em1">Ra</SPAN></SUP></SPAN></font></SPAN></SPAN> 
<SPAN CLASS="ps72" style="width: 300; left: 369; top: 554px; height: 22"><SPAN CLASS="ft2"><font color="#FF0000">When 
compared to each other, diuretics</font></SPAN></SPAN> <SPAN CLASS="ps73" style="width: 300; left: 369; top: 573px; height: 22"><SPAN CLASS="ft2"><font color="#FF0000">(hydrochlorothiazide 
with amiloride hydrochlo-</font></SPAN></SPAN> <SPAN CLASS="ps74" style="width: 300; left: 369; top: 592px; height: 19"><SPAN CLASS="ft2"><font color="#FF0000">ride) 
are superior to the beta-blocker</font></SPAN></SPAN> <SPAN CLASS="ps75" style="width: 300; left: 369; top: 609px; height: 22"><SPAN CLASS="ft2"><font color="#FF0000">atenolol.<SPAN CLASS="em2"><SUP>172<SPAN CLASS="em1">Ra</SPAN></SUP></SPAN>&#160;&#160;In 
older patients with isolated</font></SPAN></SPAN> <SPAN CLASS="ps76" style="width: 300; left: 369; top: 630px; height: 20"><SPAN CLASS="ft2"><font color="#FF0000">systolic 
hypertension, diuretics are preferred</font></SPAN></SPAN> <SPAN CLASS="ps77" style="width: 300; left: 369; top: 649px; height: 19"><SPAN CLASS="ft2"><font color="#FF0000">because 
they have significantly reduced multiple</font></SPAN></SPAN> <SPAN CLASS="ps78" style="width: 300; left: 369; top: 666px; height: 22"><SPAN CLASS="ft2"><font color="#FF0000">endpoint 
events.<SPAN CLASS="em2"><SUP>171<SPAN CLASS="em1">Ra</SPAN></SUP></SPAN></font><font color="#FFFFFF">&#160;</font>&#160;In 
addition, an RCT in</SPAN></SPAN> <SPAN CLASS="ps79" style="width: 300; left: 369; top: 687px; height: 22"><SPAN CLASS="ft2">such 
patients taking the dihydropyridine</SPAN></SPAN> <SPAN CLASS="ps80" style="width: 300; left: 369px; top: 706; height: 22"><SPAN CLASS="ft2">nitrendipine 
showed a 42-percent reduction in</SPAN></SPAN> <SPAN CLASS="ps81" style="width: 300; left: 369; top: 725px; height: 22"><SPAN CLASS="ft2">fatal 
and nonfatal stroke over an average 2-year</SPAN></SPAN> <SPAN CLASS="ps82" style="width: 300; left: 369; top: 742px; background-color: #FFFFFF; layer-background-color: #FFFFFF; border: 1px none #000000; height: 22"><SPAN CLASS="ft2">interval.<SPAN CLASS="em2"><SUP>140<SPAN CLASS="em1">Ra</SPAN></SUP></SPAN><font color="#FFFFFF">&#160;&#160;</font>The 
concomitant reductions in</SPAN></SPAN> <SPAN CLASS="ps83" style="width: 300; left: 369; top: 763px; background-color: #FFFFFF; layer-background-color: #FFFFFF; border: 1px none #000000; height: 22"><SPAN CLASS="ft2">coronary 
events and heart failure did not reach</SPAN></SPAN> <SPAN CLASS="ps84" style="width: 300; left: 369; top: 782px; height: 22"><SPAN CLASS="ft2">statistical 
significance although a favorable trend</SPAN></SPAN> <SPAN CLASS="ps85" style="width: 300; left: 369; top: 801px; height: 22"><SPAN CLASS="ft2">was 
reported and all cardiovascular disease mor-</SPAN></SPAN> <SPAN CLASS="ps86" style="width: 300; left: 369; top: 820px; height: 22"><SPAN CLASS="ft2">tality 
was significantly reduced. &#160;Because</SPAN></SPAN> <SPAN CLASS="ps87" style="width: 300; left: 369; top: 839px; height: 22"><SPAN CLASS="ft2">nitrendipine 
is not available in the United</SPAN></SPAN> <SPAN CLASS="ps88" style="width: 300; left: 369; top: 858px; height: 22"><SPAN CLASS="ft2">States, 
other long-acting dihydropyridine calci-</SPAN></SPAN> <SPAN CLASS="ps89" style="width: 300; left: 369; top: 877px; height: 22"><SPAN CLASS="ft2">um 
antagonists are considered to be appropriate</SPAN></SPAN> <SPAN CLASS="ps90" style="width: 300; left: 369; top: 896px"><SPAN CLASS="ft2">alternatives 
in these patients.</SPAN></SPAN> <span class="ps2" style="left: 25px; top: 69px; width: 325px"><span class="ft2">Hypertension 
is extremely common in older</span></span> 
<div id="Layer1" style="position:absolute; width:80px; height:16px; left: 586px; top: 956px"><a href="page46ISH&Thiazides.html" target="_self">To 
  next page</a> </div>
</BODY>

</HTML>
